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Abstract
Background: For antiretroviral therapy (ART) naive human immunodeficiency virus (HIV) infected adults suffering
from tuberculosis (TB), there is uncertainty about the optimal time to initiate highly active antiretroviral therapy
(HAART) after starting antituberculosis treatment (ATT), in order to minimize mortality, HIV disease progression, and
adverse events.
Methods: In a randomized, open label trial at All India Institute of Medical Sciences, New Delhi, India, eligible HIV
positive individuals with a diagnosis of TB were randomly assigned to receive HAART after 2-4 or 8-12 weeks of
starting ATT, and were followed for 12 months after HAART initiation. Participants received directly observed
therapy short course (DOTS) for TB, and an antiretroviral regimen comprising stavudine or zidovudine, lamivudine,
and efavirenz. Primary end points were death from any cause, and progression of HIV disease marked by failure of
ART.
Findings: A total of 150 patients with HIV and TB were initiated on HAART: 88 received it after 2-4 weeks (early
ART) and 62 after 8-12 weeks (delayed ART) of starting ATT. There was no significant difference in mortality
between the groups after the introduction of HAART. However, incidence of ART failure was 31% in delayed versus
16% in early ART arm (p = 0.045). Kaplan Meier disease progression free survival at 12 months was 79% for early
versus 64% for the delayed ART arm (p = 0.05). Rates of adverse events were similar.
Interpretation: Early initiation of HAART for patients with HIV and TB significantly decreases incidence of HIV
disease progression and has good tolerability.
Trial registration: CTRI/2011/12/002260
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Background
According to 2010 report of Joint United Nations
Programme on HIV and AIDS (UNAIDS), the global bur-
den of human immunodeficiency virus (HIV) infection
was 33.3 million in 2009, with 2.6 million incident cases
and 1.8 million acquired immune deficiency syndrome
(AIDS) related deaths [1]. Tuberculosis (TB) in HIV-
positive patients is one of the leading causes of morbidity
and mortality, and therefore, a major constraint in the
fight against HIV. Approximately 30% of HIV-infected
persons all over the world are estimated to have latent
TB infection [2]. World Health Organization (WHO)
reported in 2010 that HIV-positive population experi-
enced 11-13% of 9.4 million incident TB cases world-
wide, and 0.38 million TB related deaths during the
previous year [3]. TB is responsible for approximately
one in four deaths in HIV patients globally [4].
With about one fifth of the global burden, TB con-
tinues to be a public health challenge in India. About
40% of Indian population is supposed to be infected with
TB bacillus. The disease is responsible for 17.6% of
deaths from communicable diseases and for 3.5% of all
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causes of mortality [5]. Even though the endemic is
maintained predominantly by non HIV TB cases, the
situation gets complicated by India being the third high-
est HIV burdened country. As per 2009-2010 report
from National AIDS Control Organization (NACO), the
prevalence of HIV infection by the end of 2008 was
0.29% in Indian adults [6]. However, among TB patients
in the country, HIV prevalence was as high as 6.7% in
the same year according to WHO estimates. About
4.85% of incident TB cases in India were HIV positive in
2007 [5].
It is well established that HIV increases the risk for TB
(acquisition, reactivation and reinfection), alters its clin-
ical presentation, and reduces survival compared to
patients with TB and no HIV infection [7-9]. With intro-
duction of timely ART, the incidence of new TB infection
can also be reduced by up to 90% [10]. However, the
question is when to start highly active antiretroviral ther-
apy (HAART) in a patient with HIV and TB (HIV-TB)
who is taking treatment for tuberculosis. On one hand,
early initiation of HAART has the potential benefit of
reducing mortality and morbidity among recipients, on
the other, physicians tend to defer it during TB treatment
because of concerns that concomitant antituberculosis
and antiretroviral treatment may result in overlapping
toxicities of drugs, low adherence to medications due to
high pill burden, and higher risk of paradoxical worsen-
ing of signs/symptoms of TB that is called immune re-
constitution inflammatory syndrome (IRIS) [11]. These
factors impart considerable uncertainty to the optimal
timing of HAART initiation after starting TB treatment.
There have been several studies that deal with the
question of timing of HAART commencement in the
setting of TB treatment in order to gain optimal out-
come. Complete results of some recently concluded ran-
domized controlled trials that address the issue are yet
to come out [12,13]. Some of the published studies have
limitations like small sample size or lack of a control
group, while a few others are primarily observational or
retrospective in nature [12]. This paper presents the
findings of a randomized controlled clinical trial that
was conducted to compare early (2-4 weeks) and delayed
(8-12 weeks) initiation of antiretroviral therapy after
commencement of antituberculosis treatment in North
Indian HIV-infected adults with tuberculosis, in terms of
outcomes like mortality and HIV disease progression.
Methods
Trial design
This randomized open-label trial was conducted at All
India Institute of Medical Sciences (AIIMS), a tertiary
referral centre in New Delhi, India. ART-naïve indivi-
duals with HIV and recently diagnosed TB were enrolled
and randomized into one of the two arms of the study
using one to one allocation ratio. One arm was scheduled
to receive early HAART, starting within 2-4 weeks of
commencement of antituberculosis treatment (ATT), and
the other arm was to have delayed HAART at 8-12 weeks
after starting ATT. For TB, patients were categorized
according to Indian Revised National Tuberculosis
Control Programme (RNTCP) guidelines for thrice
weekly directly observed treatment short-course (DOTS)
[6], and treated accordingly with free drugs provided
by RNTCP. Antiretroviral drugs were provided free of
cost by NACO as part of the National AIDS Control
Programme (NACP). Patients were followed for
12 months after HAART initiation. Ethics approval for
the study was obtained from the AIIMS institutional
ethics committee.
Participants
All ART naïve HIV positive patients with active TB pre-
senting in the hospital’s ART Centre, DOTS Centre, in-
fectious diseases and chest clinics, medical OPD, and
wards were screened for eligibility. Subjects aged over
18 years, who had seven or fewer days of cumulative
previous ART (unless taken during pregnancy to prevent
mother-to-child-transmission), and who had not started
ATT or received less than 14 days of the same, were eli-
gible for entry into this study. Both confirmed and prob-
able diagnoses of TB were permitted for inclusion.
Confirmed cases included those with positive smear
(using Ziehl Neelsen staining) for acid fast bacilli, and/or
culture growth (on solid Lowenstein Jensen medium).
As per WHO guidelines, probable diagnosis is based on
the clinician’s judgment where acid-fast bacilli are not
demonstrable but sufficient clinical suspicion and/or
radiological evidence exists to initiate empiric TB ther-
apy [14]. Liver function tests, i.e. SGOT, SGPT, and
serum bilirubin, within five times the upper limit of nor-
mal range, and for female subjects, a negative urine
pregnancy test were required for study entry. Exclusion
criteria were pregnancy, concomitant diabetes mellitus,
epilepsy, severe illness (e.g. loss of consciousness, severe
hempotysis etc.), and multi-drug resistant TB (MDR
TB). MDR TB was excluded by a positive history of the
same. Besides, all sputum samples positive for Mycobac-
terium tuberculosis were further screened using radio-
metric BACTEC 460 TB system.
Interventions
Patients who satisfied the screening criteria and provided
written informed consent had their HIV status con-
firmed using Enzyme-linked Immunosorbent Assay
(ELISA) test for HIV. Three sets of ELISA tests were
done according to NACO guidelines [15,16]. A sample
testing reactive by the first test (SD BIOLINE HIV 1/2 ),
underwent a second (PAREEKSHAK TRILINE HIV ½)
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and a third (PAREEKSHAK TRISPOT HIV 1/2 ) test
based on different principles or different antigen systems.
A sample testing reactive for all three tests was termed
HIV seropositive. Once HIV status was confirmed,
patients were registered in the ART clinic with permanent
ART numbers. All patients underwent pre-registration
assessment, consisting of complete history and physical
examination with measurement of height, weight and
body mass index (BMI). Laboratory investigations for
each included plasma HIV RNA viral load and CD4 cell
count; complete blood count (CBC), erythrocyte sedi-
mentation rate (ESR), and serum biochemistry; smear for
acid fast bacilli, culture and drug sensitivity for TB, and
in some cases PCR of sputum or other specimens; diag-
nostic imaging like roentogram, ultrasonography, or
computed tomography as indicated for TB diagnosis;
histology or cytopathology of lymph nodes, abscesses or
body fluids if indicated; routine urine and stool micros-
copy for evidence of other opportunistic infections; and
testing for hepatitis B (HBsAg) and hepatitis C (anti-
HCV IgG) infections.
As per the study protocol, all HIV-TB patients received
ART regardless of CD4 cell count. Antiretroviral regimen
consisted of stavudine (d4T) 30 mg or zidovudine (ZDV)
300 mg twice daily, along with lamivudine (3TC) 150 mg
twice daily and efavirenz (EFV) 600 mg once daily. EFV
was replaced with nevirapine at the end of TB treatment.
Patients who developed ZDV- induced anaemia during
the course of HAART had ZDV replaced with d4T.
All the study participants who had CD4 cell count
<200/mm3, were given trimethoprim-sufamethoxazole
(TMP-SMZ), one double strength tablet once daily for
Pneumocystis prophylaxis.
Since baseline visit at the initiation of HAART,
patients from both the groups were followed every
month till 12 months of ART. At follow up visits, each
patient underwent a targeted history and physical exam-
ination, blood tests including serum biochemistry, CBC
and ESR, and other relevant investigations based on clin-
ical findings. CD4 cell counts were measured by flow
cytometry using BD FACS CALIBUR and flourocein
monoclonal antibodies (Beckton Dickenson Biosciences,
California, USA) at baseline, two, six, nine, and
12 months of follow up. The HIV RNA viral load was
measured by Roche Amplicor (Amplicor HIV-1 Monitor
Test, version 1.5, Branchburg, NJ: Roche Diagnostics;
2003) at baseline, six, and twelve months. A sputum
examination was done before the start of ATT, and at
two and six months of ATT. Chest roentgenogram was
done at baseline, at six months post ATT, and at the
time of Immune Reconstitution Inflammatory syndrome
(IRIS), if applicable. All patients coming for follow up
visits were assessed for adverse events including IRIS,
and the emergence of any opportunistic infections.
Outcomes
The primary end points of the study were death from any
cause and antiretroviral treatment failure, as a measure
of progression of HIV disease. Death was documented
from hospital death certificates, or by communication
with the patient’s family or health care provider. As per
NACO guidelines, a patient was said to have ART failure
if any of the following occurred after at least six months
of ART: - Clinical failure: new or recurrent WHO stage
four condition; Immunological failure: a fall of CD4
count to below pre-therapy baseline, or a 50% decline
in CD4 count from the on – treatment peak value, or
persistent CD4 levels below 100 cells /mm3; virological
failure: plasma viral load >10,000 copies/ml [17]. The
secondary end points of the study were defined by
safety and tolerability of ARV therapy, as assessed by
the incidence of adverse events and proportion of sub-
jects changing/ discontinuing ARV therapy because of
the same. Outcome of TB treatment as defined by
WHO [18], CD4 cell count and HIV RNA viral load,
and assessment of general health by blood haemoglobin
level and BMI at 6 and 12 months of ART were other
secondary outcomes.
Sample size
The null hypothesis of this study states that there is no
difference in terms of all cause mortality and progression
of HIV disease between HIV patients with tuberculosis
who start HAART early (at 2-4 weeks) and those who
receive it delayed (at 8-12 weeks) after commencement
of antituberculosis chemotherapy. Since it was one of
the first studies on this topic from India, a target sample
size of 75 patients per arm was decided as the sample
size of convenience as per protocol.
Randomization
2 weeks after starting ATT, patients were allocated by
computer generated sequence of random numbers to
one of the two groups of the study in one to one ratio,
following simple randomization. The sequence was gen-
erated by the statistician, and the study being open label,
was known to the research team, which enrolled the par-
ticipants as well as assigned them to study groups. ART
physicians were informed of each patient’s allocation
after randomization. Neither participants nor care provi-
ders were blinded to interventions.
Statistical methods
All the pertinent clinical and laboratory data on individ-
ual subjects were entered into the case report forms,
and transferred to an electronic data base with 100%
retrospective data auditing. The electronic data was
exported into the STATA software, version 11, for
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statistical analysis. All the analyses were performed as
per the modified intention-to-treat principle with inclu-
sion of only those patients who initiated HAART at the
place of the study. The analyst was kept blind to the
interventions. Primary end points of the study were
assessed using Kaplan Meier analysis and log rank com-
parisons. Fisher’s exact test was used for analysis of cat-




Figure 1 shows the screening and enrolment of partici-
pants in the study. A total of 181 patients were rando-
mized, with 92 going to the early ART arm and 89 to the
delayed ART arm. Fifteen of them (two from early ART
and 13 from delayed ART groups) did not come back for
HAART initiation, while seven others (two from early
ART and five from delayed ART arms) could not start
HAART before completion of their ATT. Besides, nine
patients from the delayed ART arm started HAART earl-
ier elsewhere and did not come for follow up. The
remaining 150 patients were initiated on HAART as part
of the study: 88 received it within 2-4 weeks (early
group) of starting ATT, and 62 within 8-12 weeks
(delayed group) of the same. At the time of the final
analysis, 122 (81.3%) patients out of 150 had completed
follow up of 12 months, 68 in early and 54 in delayed
ART groups respectively. Sixteen (10.7%) patients, nine
(10.2%) from early and seven (11.3%) from delayed ART
group, had died, and 12 (8.0%) were lost to follow up, 11
(12.5%) in the early arm and one (1.6%) in the delayed
arm. ‘Lost to follow up’ was defined by failure to visit the
hospital for three consecutive months. Out of the total
12 patients lost to follow up, five were untraceable (no
telephonic contact could be made), four were transferred
to other ART centres due to spatial relocation, and three
had defaulted treatment.
1552 ART naïve HIV cases were screened
181 underwent randomization 
1371 were excluded: 
• 963 did not have TB 
• 172 declined participation 
• 109 had already taken ATT for >14 days 
• 93 did not return for randomization 
• 13 had deranged liver function tests 
• 7 were seriously ill 
• 5 were pregnant 
• 5 had uncontrolled blood sugar level 
• 4 had history of multidrug resistant TB 
92 went to early ART group 89 went to delayed ART group 
88 started ART within 2-4 
weeks of initiation of ATT 
4 were excluded: 
• 2 could not start ART in time 
• 2 did not return to start ART 
62 started ART within 8-12 
weeks of initiation of ATT 
27 were excluded: 
• 13 did not return to start ART 
• 9 started ART earlier elsewhere 
• 5 could not start ART in time 
• 68 completed 12 months follow up • 54 completed 12 months follow up 
20 could not complete 12 
months follow up: 
• 11 were lost to follow up 
• 9 died 
8 could not complete 12 
months follow up: 
• 7 died 
• 1 was lost to follow up 
Figure 1 Screening, Enrolment, and Follow-up of study participants.
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Recruitment
All the patients enrolled till March 31, 2011, were
included in the final analysis. The duration of follow up
in the study was calculated as the time from initiation of
HAART to death, loss to follow up, or the completion of
12 months whichever came earlier.
Baseline data
Group-wise baseline demographic and clinical character-
istic of 150 enrolled patients is presented in Table 1.
Both the groups were found to be homogeneous with
each other, having similar initial BMI, age distribution,
and sex ratio (with significant male predominance). The
median gaps between commencement of ATT and ART
in early and delayed groups were 19 and 63 days respect-
ively. No significant difference was seen between the
groups in terms of baseline median CD4 count, viral
load, and other laboratory parameters. Most patients
were new cases of TB, and therefore, received DOTS
category I ATT (94.3% in the early ART group, 98.4% in
delayed ART group). According to RNTCP guidelines,
they received isoniazid (H) 600 mg, rifampicin (R)
450 mg (600 mg if body weight ≥60 kg), pyrazinamide
(Z) 1500 mg, and ethambutol (E) 1200 mg thrice weekly
during the intensive treatment phase of two months, fol-
lowed by isoniazid 300 mg and rifampicin 450 mg thrice
weekly in the continuation phase for 4 months
(2H3R3Z3E3 + 4H3R3). Six patients, who had been trea-
ted for a different episode of TB in the past, received
DOTS category II ATT (five in early ART and one in
delayed ART group). Intensive phase of RNTCP DOTS
category II ATT lasts for three months, with strepto-
mycin (S) 750 mg (500 mg if age >50 years) given
thrice weekly for first two months, in addition to
H3R3Z3E3. In continuation phase, category II patients
received isoniazid, rifampicin, and ethambutol for
5 months (2H3R3Z3E3S3 + 1H3R3Z3E3 + 5H3R3E3) [5,6].
Even though the early ART group has apparently
higher number of cases of EPTB with dissemination,
no statistically significant difference was found between
the two arms of the study with respect to any type of
TB individually, or overall.
Primary outcome
All 150 patients, 88 in the early ART group and 62 in
the delayed ART group, were included in the analysis for
primary outcome measures of death from any cause and
ART failure. The overall mortality was found to be
10.7% (16/150), 10.2% (9/88) in the early ART group and
11.3% (7/62) in the delayed ART group (p value = 0.773).
This translates to death rates of 13.8 and 13.0 per 100
person years for the two groups respectively. It was seen
that out of 16 patients who died during the follow up,
11 (68.8%) had baseline CD4 value <100 cells/mm3,
seven coming from the early and four from the delayed
ART groups.
Table 2 shows the comparative outcome of antiretro-
viral treatment in the two groups of the study. The inci-
dence of immunological failure was seen to be
significantly higher at 22.6% (14/62) in the delayed ART
group, in comparison with 9.1% (8/88) in the early ART
group (p = 0.033). Only one patient of all 150 went into
clinical failure, and he was from the delayed ART group









Mean ± SD 34.86 ± 8.1 34.82 ± 7.6 0.97
Gender, number (%):
Male 74 (84.1%) 52 (83.9%)
Female 14 (15.9%) 10 (16.1%) 0.971
BMI, kg/m2:
Mean ± SD 17.9 ± 2.8 18.4 ± 2.1
Hemoglobin, mg/dl
Mean ± SD 10.6 ± 1.7 11.0 ± 1.9
CD4 count, cells/mm3:
Median 133 152




Non TB OI’s :
number (%) 12 (13.6%) 10 (16.1%) 0.671
WHO Staging of HIV disease, number (%):
Stage 3 19(21.6%) 15 (24.2%) 0.70
Stage 4 69 (78.4%) 47 (75.8%) (overall)
Type of Tuberculosis, number (%):
PTB 19 (21.6%) 15 (24.2%)
PTB with Dissemination 33 (37.5%) 26 (41.9%) 0.367
EPTB 18 (20.4%) 15 (24.2%) (overall)
EPTB with Dissemination 18 (20.4%) 06 (09.7%)
DOTS Category of ATT, number (%):
Category I (2H3R3Z3E3 + 4H3R3) 83 (94.3%) 61 (98.4%) 0.214
Category II (2H3R3Z3E3S3 +
1H3R3Z3E3 + 5H3R3E3)
05 (5.7%) 01 (1.6%) (overall)
SD = Standard deviation; BMI = Body Mass Index; OI’s = Opportunistic
Infections; WHO = World Health Organization; HIV = Human
immunodeficiency virus; PTB = Pulmonary Tuberculosis; EPTB = Extra
Pulmonary Tuberculosis; ATT = Antituberculosis treatment; H = Isoniazid
(600 mg), R = Rifampicin (450 mg), Z = Pyrazinamide (1500 mg), E =
Ethambutol (1200 mg), S = Streptomycin (750 mg).
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(0.0% vs.1.6%, p = 0.413). Virological failure was docu-
mented in 8 patients from each group, its incidence
being 9.1% in the early and 12.9% in the delayed ART
groups (p = 0.592). Rate of overall treatment failure was
observed to be almost double in the delayed ART group
(31%), as compared to that in the early ART group (16%)
(p = 0.045). The incidence of failure of ARV therapy in
the entire study population was 22%.
Based on the incidence of various types of treatment
failure over the follow up period, 12 months HIV disease
progression free survival rate was calculated for each
group. At 79%, it was significantly better for the early
ART group, as against 64% for the delayed ART group
(p = 0.05). A Kaplan-Meier disease progression free sur-
vival curve was plotted on the basis of the same calcula-
tion and is depicted in Figure 2.
Secondary outcomes
Among the adverse events, immune reconstitution in-
flammatory syndrome was diagnosed in nine patients
(10.2%) in the early ART group and six patients (9.7%) in
the delayed ART group (p = 0.571). The median time of
occurrence of IRIS after initiation of HAART was 73
and 68.5 days in the early and delayed ART groups re-
spectively. All cases of IRIS were of mild to moderate se-
verity, and none of them required any interruption of
HAART or management with steroids. The affected
patients responded well to antipyretic (paracetamol) and
analgesics (non-steroidal anti-inflammatory drugs).
The incidence of other adverse events was also not sig-
nificantly different between the groups (23.9% in the
early and 22.6% in the delayed ART group, p = 0.855).
Seven patients (4%) required a change in the antiretro-
viral regimen, in which zidovudine was switched for sta-
vudine, due to the development of drug induced severe
anaemia. Four (4.5%) of them came from the early ART
group and three (4.8%) from the delayed ART group
(p = 0.612). No change in therapy was needed for any
other adverse event. All of them were managed appro-
priately by experts at the respective follow up clinics of
the patients. No death in the study population was
attributed to any of the adverse events.
Outcome of antituberculosis treatment was cate-
gorised as per the WHO definitions [19]. At the time of
final analysis, all study participants had completed their
Table 2 Outcomes of Antituberculosis and Antiretroviral
Treatment






Successfully treated 93.4% (71/76) 93.1% (54/58) 0.105 (Overall)
Failure 6.6% (5/76) 5.2% (3/58)
Treatment Modified 1.3% (1/76) 1.7% (1/58)
Losses during ATT:
Died 06 (6.8%) 04 (6.4%)
Lost to Follow Up 06 (6.8%) 00 (0.0%)






HIV Disease Progression 14 (16%) 19 (31%) 0.045
Clinical Failure 00 (0%) 01 (1.6%) 0.413
Immunological failure 08 (9.1%) 14 (22.6%) 0.033
Virological failure 08 (09.1%) 08 (12.9%) 0.592
Lost to follow up 11 (12.5%) 01 (1.6%)
ART = Antiretroviral therapy, ATT = Antituberculosis treatment.
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Figure 2 Kaplan Meier Curve of Survival without progression of HIV disease for 12 Months with Early and Delayed ART.
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prescribed ATT courses. Six (6.8%) patients from early
and four (6.4%) from delayed ART group had died, and
further six patients from the early ART group were lost
to follow up before the completion of their antitubercu-
losis therapy. No significant difference was seen in the
outcome of TB treatment at the completion of ATT be-
tween the groups (p = 0.105), as summarized in Table 2.
During follow up, one case of relapse of TB has been
reported from each group till date.
Response of the patients to overall treatment was simi-
lar in each group in terms of general health parameters
like haemoglobin level, liver function tests and body
mass index (Table 3).
Discussion
This is the first study sponsored by National AIDS Con-
trol Organization, Ministry of Health & Family Welfare,
Government of India in this topic. The results of this
study show that once highly active antiretroviral therapy
(HAART) is started, there is no significant difference in
mortality between HIV-TB patients who were started on
HAART 2-4 weeks after initiation of antituberculosis
treatment (early ART group), and those who received it
8-12 weeks after starting ATT (delayed ART group).
However, the risk for progression of HIV disease, as
estimated by onset of failure of ARV therapy, increases
significantly if initiation of HAART is deferred from
2-4 weeks to 8-12 weeks (16% vs. 31% risk, p = 0.045).
The incidence of IRIS and other adverse events, and out-
come of TB treatment are similar between the groups.
To decide the optimal timing for initiation of HAART
after starting ATT in HIV-TB patients has been listed as
a priority research question for resource limited settings
by WHO [20]. Several studies have been involved with
the task of finding a definitive answer to it so that mor-
tality and serious morbidity could be minimized in this
patient population [12,21]. A recent trial by Abdool
Karim et al shows that starting antiretroviral therapy at
CD4 cell count <500/mm3 during treatment for AFB
smear-positive TB (integrated therapy) reduces mortality
by 56% in HIV-TB cases, as compared to delaying it
until the completion of TB therapy (sequential therapy)
[22]. They have reported an all-cause mortality rate of
5.4 per 100 person-years in the integrated therapy arm
as compared to 12.1/100 per year in the sequential ther-
apy arm (p = 0.003). Their integrated therapy arm corre-
sponds roughly with both the groups of the present
study taken together, where the combined mortality rate
was observed to be 13.4/100 per year. The main reason
for this apparently higher mortality observed here may
be that the current study had a much higher percentage
(77.3%) of patients in WHO stage four HIV disease at
baseline than that (4.9%) in the South African study.
Another trial at Cambodia has shown in its prelimin-
ary report that there is a significant survival advantage
of 34% in starting HAART at two weeks (early arm) ra-
ther than at eight weeks (late arm) after initiation of TB
treatment [19,23]. They observed a mortality of 17.8% in
the early arm against 27.4% in the late arm (p = 0.002).
On comparison, it can be seen that the Cambodian
study reports a much higher mortality rate in both the
groups than the present study despite both following a
similar protocol in terms of timing of ART initiation.
One of the important reasons for this difference may be
their exclusive enrolment of patients with CD4 count
<200/mm3. For the same reason, it can be argued that
results of the current study are more generalizable than
the Cambodian one. Moreover, while the present re-
search work has excluded the deaths that might have oc-
curred between the starting of ATT and ART in both
the groups, this fraction was taken into account while
calculating mortality in the Cambodian project.
The current research was designed to assess and com-
pare the response of HAART in HIV-TB patients who
started it 2-4 weeks after starting TB therapy and those
who received it 8-12 weeks after starting TB treatment.
CD4 cell counts and plasma viral load have been consid-
ered important markers for assessment of response to
ARV therapy and disease progression [24-26]. Previous
studies have shown that co-infection with TB results in
reduced survival, increased risk for other opportunistic
infections and elevations in HIV replication [27,28].
Table 3 Health Parameters at Different Time Points
Variable# Group!
Time!
Early ART Delayed ART
Baseline 6 months 12 months Baseline 6 months 12 months
Bilirubin, mg/dL: Mean ± SD 0.6 ± 0.2 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1
SGOT, IU/L: Mean ± SD 51.1 ± 29.6 48.3 ± 20.8 35.8 ± 17.1 47.6 ± 20.9 40.2 ± 19.8 33.6 ± 9.9
SGPT, IU/L: Mean ± SD 39.1 ± 23.7 42.4 ± 19.4 31.1 ± 11.6 40.3 ± 20.2 34.1 ± 14.1 33.2 ± 17.7
Hemoglobin, g/dL: Mean ± SD 10.2 ± 1.8 12.2 ± 1.9 12.8 ± 1.3 10.6 ± 1.8 12.3 ± 1.5 12.8 ± 1.4
ESR, mm/1st hour: Mean ± SD 46.0 ± 23.8 28.7 ± 17.2 25.7 ± 11.5 43.0 ± 24.6 32.4 ± 15.2 22.0 ± 9.9
BMI, kg/m2: Mean ± SD 17.9 ± 2.8 19.9 ± 2.5 20.7 ± 2.7 18.4 ± 2.1 20.2 ± 2.4 20.9 ± 2.5
ART = Antiretroviral therapy; SD = Standard deviation; SGOT = Serum Glutamate Oxaloacetate Transaminase; SGPT = Serum Glutamate Pyruvate Transaminase.
ESR = Erythrocyte Sedimentation Rate; BMI = Body mass index.
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Increased HIV replication is attributed to activation of
latently infected cells, and promotion of infection in un-
infected lymphocytes and macrophages. HIV genetic di-
versity is also increased in the presence of active TB
infection [29-31]. The results of this study indicate that
these processes may be significant enough to cause fail-
ure of ARV therapy after a few months, warranting a
switch to second line ART. Some previous studies have
demonstrated that death in HIV-TB patients within the
first few months of TB treatment may be related to TB,
whereas late deaths are attributable to HIV disease pro-
gression [32-34]. Therefore, it can be extrapolated that
in due course of time a differential disease progression
might even translate into a significant difference in mor-
tality between the two groups of the study. In light of
this observation, the present work supports 2010 WHO
recommendations for the management of HIV-TB cases:
[35]
1. Start ART in all HIV-infected individuals with active
TB, irrespective of the CD4 cell count.
2. Start TB treatment first, followed by ART as soon as
possible afterwards (and within the first eight
weeks).
The overall incidence of Immune Reconstitution In-
flammatory Syndrome observed here (10.0%) is close to
that reported for the integrated therapy arm (12.4%) by
Abdool Karim et al [27]. The Cambodian trial has
reported a significantly higher incidence of IRIS in the
early ART arm (4.03 per 100 patient months) than in the
late arm (1.44/100 pm, p <0.0001) [28], but no such dif-
ference could be seen in the present study.
This research work has a few limitations. Here all
cause mortality was taken as the primary outcome in-
stead of disease-specific death rate. While the latter
would be more suitable for assessment of response to
ART, there were logistic difficulties in ascertaining the
exact cause of most of the deaths, as they happened
away from the hospital. Another limitation is introduced
by the uneven number of lost to follow up patients (11
in early ART and one in delayed ART) in the two groups
of the study, which could affect its results. But seven of
them from early ART arm were known to be alive by the
end of 12 months since they were initiated on ART, and
the consideration of the worst outcome for the five (four
in early ART arm and one in delayed ART arm) untrace-
able patients did not alter the overall results of the study
significantly. In addition, as decided in the approved
protocol, sample size of the study was based on a target
of convenience rather than on power calculations. In this
study given a baseline rate of 10% mortality, there was
an 80% power to detect a difference of 18% mortality be-
tween early and delayed ART groups. However, despite
these limitations, being one of the first studies on this
topic from India, the present work will serve as one of
the resources for early starting of ARV treatment under
National AIDS Control Programme. It will also help for
any future metaanalysis for the timing of HAART initi-
ation in HIV-TB cases.
This study presents important research findings
regarding optimal time to initiate ART in HIV-TB cases
so that detrimental effects of both the diseases can be
minimized. Since it included HIV patients irrespective of
baseline CD4 cell counts and with different types of TB,
its results can be fairly generalized. It brought to light
the observation that starting early ART in HIV-TB
patients helps control the progression of HIV disease
later on, and hence, it suggests that all such patients
must be started on HAART as soon as possible after ini-
tiation of TB treatment.
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